Xilio Therapeutics, Inc. (NASDAQ:XLO) Short Interest Update

Xilio Therapeutics, Inc. (NASDAQ:XLOGet Rating) saw a significant growth in short interest in April. As of April 30th, there was short interest totalling 326,200 shares, a growth of 47.0% from the April 15th total of 221,900 shares. Based on an average daily volume of 34,200 shares, the days-to-cover ratio is currently 9.5 days. Currently, 3.3% of the shares of the stock are sold short.

Shares of Xilio Therapeutics stock opened at $3.37 on Friday. The company has a current ratio of 15.85, a quick ratio of 15.85 and a debt-to-equity ratio of 0.05. Xilio Therapeutics has a 12 month low of $2.81 and a 12 month high of $27.95. The business’s 50-day moving average price is $5.90 and its 200-day moving average price is $11.86.

Xilio Therapeutics (NASDAQ:XLOGet Rating) last issued its earnings results on Tuesday, March 1st. The company reported ($0.98) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.04). As a group, sell-side analysts anticipate that Xilio Therapeutics will post -3.45 earnings per share for the current fiscal year.

Separately, Zacks Investment Research lowered shares of Xilio Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, March 15th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $24.67.

Several hedge funds have recently added to or reduced their stakes in XLO. RiverVest Venture Management LLC bought a new stake in Xilio Therapeutics in the fourth quarter worth $23,063,000. Monashee Investment Management LLC purchased a new position in shares of Xilio Therapeutics in the fourth quarter worth about $3,428,000. Wells Fargo & Company MN purchased a new position in shares of Xilio Therapeutics in the fourth quarter worth about $71,000. California State Teachers Retirement System bought a new stake in shares of Xilio Therapeutics in the 4th quarter valued at about $65,000. Finally, Citigroup Inc. bought a new position in Xilio Therapeutics during the 4th quarter worth approximately $35,000. 72.33% of the stock is currently owned by institutional investors.

About Xilio Therapeutics (Get Rating)

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors.

Featured Stories

Receive News & Ratings for Xilio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xilio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.